Stehlé Thomas, El Karoui Khalil, Sakka Mehdi, Ismail Ahmad, Matignon Marie, Grimbert Philippe, Canoui-Poitrine Florence, Prié Dominique, Audard Vincent
Assistance Publique des Hôpitaux de Paris (AP-HP), Groupe Hospitalier Henri-Mondor/Albert Chenevier, Service de Néphrologie et Transplantation, Creteil, France.
Université Paris Est Créteil (UPEC), Institut National de la Santé et de la Recherche Médicale (INSERM) U955, Institut Mondor de Recherche Biomédicale (IMRB), Équipe 21, Créteil, France.
Clin Kidney J. 2019 Jul 21;13(4):587-596. doi: 10.1093/ckj/sfz087. eCollection 2020 Aug.
Creatinine clearance after cimetidine administration (Cim-CreatClr) was once proposed as a method of glomerular filtration rate (GFR) measurement, but has been largely abandoned. We investigated whether a new short procedure for Cim-CreatClr determination could be considered an appropriate method for GFR measurement.
A 150-min protocol involving oral cimetidine administration was developed to determine Cim-CreatClr. In total, 168 patients underwent simultaneous assessments of creatinine clearance before and after cimetidine administration [basal creatinine clearance (Basal-CreatClr) and Cim-CreatClr, respectively], renal iohexol clearance and plasma iohexol clearance (R-iohexClr and P-iohexClr, respectively). We compared the agreement between the various methods of GFR measurement, using Bland-Altman plots to determine biases, precisions (standard deviation of the biases) and accuracy (proportions of GFR values falling within 10, 15 and 30% of the mean: P10, P15 and P30, respectively).
After cimetidine administration, Basal-CreatClr decreased by 19.8% [95% reference limits of agreement (95% LoA): -2.2 to 41.7%]. The bias between Cim-CreatClr and P-iohexClr was -0.6% (95% LoA -26.8 to 28%); the precision was 14.0%; P10, P15 and P30 were 57.1% [95% confidence interval (95% CI) 49.3 to 64.7%], 73.2% (95% CI 65.8 to 79.7%) and 97.0% (95% CI 93.2 to 99.0%), respectively. Due to the positive bias (16.7%; 95% LoA -3.6 to 36.9%) of Cim-CreatClr relative to R-iohexClr, accuracy of Cim-CreatClr relative to R-iohexClr was poor despite a good precision (10.3%).
Our study shows a high level of agreement between Cim-CreatClr and P-iohexClr. These results suggest that this short Cim-CreatClr procedure is a valid method for GFR measurement, which might be useful, in particular, in situations in which P-iohexClr is not suitable or not available.
西咪替丁给药后的肌酐清除率(Cim-CreatClr)曾被提议作为一种测量肾小球滤过率(GFR)的方法,但如今已基本被弃用。我们研究了一种用于测定Cim-CreatClr的新的简短程序是否可被视为一种合适的GFR测量方法。
制定了一个涉及口服西咪替丁的150分钟方案来测定Cim-CreatClr。总共168例患者在西咪替丁给药前后同时接受了肌酐清除率评估[分别为基础肌酐清除率(Basal-CreatClr)和Cim-CreatClr]、肾脏碘海醇清除率和血浆碘海醇清除率(分别为R-iohexClr和P-iohexClr)。我们使用Bland-Altman图比较了各种GFR测量方法之间的一致性,以确定偏差、精密度(偏差的标准差)和准确性(GFR值落在均值的10%、15%和30%范围内的比例:分别为P10、P15和P30)。
西咪替丁给药后,Basal-CreatClr下降了19.8%[一致性的95%参考限(95% LoA):-2.2%至41.7%]。Cim-CreatClr与P-iohexClr之间的偏差为-0.6%(95% LoA -26.8%至28%);精密度为14.0%;P10、P15和P30分别为57.1%[95%置信区间(95% CI)49.3%至64.7%]、73.2%(95% CI 65.8%至79.7%)和97.0%(95% CI 93.2%至99.0%)。由于Cim-CreatClr相对于R-iohexClr存在正偏差(16.